Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2017 from OUS - Genetics (Lothe)

15 publications found

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Mol Cancer, 16 (1), 116
DOI 10.1186/s12943-017-0691-y, PubMed 28683746

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J (2017)
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
Ann Oncol, 28 (5), 1023-1031
DOI 10.1093/annonc/mdx052, PubMed 28453697

Dukic AR, Haugen LH, Pidoux G, Leithe E, Bakke O, Taskén K (2017)
A protein kinase A-ezrin complex regulates connexin 43 gap junction communication in liver epithelial cells
Cell Signal, 32, 1-11
DOI 10.1016/j.cellsig.2017.01.008, PubMed 28077322

Eide PW, Bruun J, Lothe RA, Sveen A (2017)
CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
Sci Rep, 7 (1), 16618
DOI 10.1038/s41598-017-16747-x, PubMed 29192179

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999

Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA (2017)
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
Mol Oncol, 11 (9), 1156-1171
DOI 10.1002/1878-0261.12086, PubMed 28556483

Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630

Leithe E, Mesnil M, Aasen T (2017)
The connexin 43 C-terminus: A tail of many tales
Biochim Biophys Acta Biomembr, 1860 (1), 48-64
DOI 10.1016/j.bbamem.2017.05.008, PubMed 28526583

Lind GE, Guriby M, Ahlquist T, Hussain I, Jeanmougin M, Søreide K, Kørner H, Lothe RA, Nordgård O (2017)
Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients
Clin Epigenetics, 9, 97
DOI 10.1186/s13148-017-0397-4, PubMed 28878843

Mesnil M, Aasen T, Boucher J, Chépied A, Cronier L, Defamie N, Kameritsch P, Laird DW, Lampe PD, Lathia JD, Leithe E, Mehta PP, Monvoisin A, Pogoda K, Sin WC, Tabernero A, Yamasaki H, Yeh ES, Dagli MLZ, Naus CC (2017)
An update on minding the gap in cancer
Biochim Biophys Acta Biomembr, 1860 (1), 237-243
DOI 10.1016/j.bbamem.2017.06.015, PubMed 28655619

Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA (2017)
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Clin Cancer Res, 24 (4), 794-806
DOI 10.1158/1078-0432.CCR-17-1234, PubMed 29242316

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Genome Med, 9 (1), 46
DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Totland MZ, Bergsland CH, Fykerud TA, Knudsen LM, Rasmussen NL, Eide PW, Yohannes Z, Sørensen V, Brech A, Lothe RA, Leithe E (2017)
The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions
J Cell Sci, 130 (17), 2867-2882
DOI 10.1242/jcs.202408, PubMed 28733455

Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE (2017)
CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
Int J Cancer, 141 (5), 967-976
DOI 10.1002/ijc.30796, PubMed 28542846

 
Page visits: 72935